[go: up one dir, main page]

ZA924150B - Vaccine for human immunodeficiency virus - Google Patents

Vaccine for human immunodeficiency virus

Info

Publication number
ZA924150B
ZA924150B ZA924150A ZA924150A ZA924150B ZA 924150 B ZA924150 B ZA 924150B ZA 924150 A ZA924150 A ZA 924150A ZA 924150 A ZA924150 A ZA 924150A ZA 924150 B ZA924150 B ZA 924150B
Authority
ZA
South Africa
Prior art keywords
vaccine
immunodeficiency virus
human immunodeficiency
human
virus
Prior art date
Application number
ZA924150A
Inventor
Gale E Smith
E Smith Gale
Franklin Volvovitz
Volvovitz Franklin
Original Assignee
Microgenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microgenesys Inc filed Critical Microgenesys Inc
Publication of ZA924150B publication Critical patent/ZA924150B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA924150A 1991-06-11 1992-06-08 Vaccine for human immunodeficiency virus ZA924150B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71415291A 1991-06-11 1991-06-11

Publications (1)

Publication Number Publication Date
ZA924150B true ZA924150B (en) 1993-02-24

Family

ID=24868938

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA924150A ZA924150B (en) 1991-06-11 1992-06-08 Vaccine for human immunodeficiency virus

Country Status (18)

Country Link
EP (1) EP0542998A1 (en)
JP (1) JPH06501851A (en)
CN (1) CN1068266A (en)
AU (2) AU2193192A (en)
BG (1) BG97519A (en)
CA (1) CA2087732A1 (en)
EE (1) EE9400183A (en)
FI (1) FI930577A (en)
HU (1) HUT68355A (en)
IE (1) IE921875A1 (en)
IL (1) IL102092A (en)
LT (1) LT3365B (en)
MX (1) MX9202781A (en)
PL (1) PL297849A1 (en)
PT (1) PT100584A (en)
SK (1) SK18993A3 (en)
WO (1) WO1992022654A1 (en)
ZA (1) ZA924150B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
CA2179394A1 (en) * 1993-12-23 1995-06-29 Kostas Iatrou Methods of expressing proteins in insect cells and methods of killing insects
NZ311319A (en) 1995-06-07 2000-01-28 Trimeris Inc The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
EP1578766B1 (en) * 2002-12-03 2013-02-13 University of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
ES2357430T3 (en) 2003-10-24 2011-04-26 Immunaid Pty Ltd THERAPY METHOD
PA8809601A1 (en) 2007-12-24 2009-07-23 Cipla Ltd ANTI-RETROVIRAL COMBINATION
EP2435825B8 (en) 2009-05-27 2015-09-02 Biotempus Limited Methods of treating diseases
JP5845265B2 (en) 2011-08-19 2016-01-20 オーストリッチファーマ株式会社 Antibody and antibody-containing composition
CN102961760B (en) * 2011-09-01 2017-07-18 常州文松生物技术有限公司 Overlapping peptide is used as reagent and its application for preparing Skin-test and detection specific cellular immunity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

Also Published As

Publication number Publication date
CN1068266A (en) 1993-01-27
PL297849A1 (en) 1994-01-24
IL102092A (en) 1996-11-14
EP0542998A1 (en) 1993-05-26
PT100584A (en) 1993-07-30
FI930577A0 (en) 1993-02-10
EE9400183A (en) 1995-12-15
MX9202781A (en) 1993-04-01
JPH06501851A (en) 1994-03-03
IE921875A1 (en) 1992-12-16
HUT68355A (en) 1995-06-28
LTIP335A (en) 1995-01-31
LT3365B (en) 1995-07-25
WO1992022654A1 (en) 1992-12-23
BG97519A (en) 1994-03-24
HU9300686D0 (en) 1993-06-28
SK18993A3 (en) 1993-10-06
AU4028895A (en) 1996-02-22
AU2193192A (en) 1993-01-12
IL102092A0 (en) 1993-01-14
CA2087732A1 (en) 1992-12-12
FI930577A (en) 1993-03-24

Similar Documents

Publication Publication Date Title
LTIP335A (en) Vaccine for human immunodeficiency virus
ZA922011B (en) Vaccine
CZ197595A3 (en) Vaccine preparations
HUP9601466A2 (en) Adjuvants for viral vaccines
ZA936592B (en) Nutrition for persons infected with human immunodeficiency virus
HUP9601462A2 (en) Adjuvants for viral vaccines
EP0631506A4 (en) Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines.
GB9106048D0 (en) Vaccines
HU9300010D0 (en) Glycoprotein vaccine named ehv-4
GB9210337D0 (en) Feline leukaemia virus vaccine
HU9203976D0 (en) Vaccine based on modified herpes virus
ZA935165B (en) Developments relating to human immunodeficiency viruses
GB9109763D0 (en) Herpes virus vaccine
GB9111574D0 (en) Developments relating to human immunodeficiency viruses
GB9020799D0 (en) Viral vaccines
GB9020584D0 (en) Vaccine
IL94510A0 (en) Influenza vaccine
GB8712042D0 (en) Virus & vaccine
GB9114714D0 (en) Herpesvirus vaccine
GB9222156D0 (en) Vaccine
GB9206786D0 (en) Vaccine
GB9206788D0 (en) Vaccine
GB9213308D0 (en) Vaccine
GB9206789D0 (en) Vaccine
GB9206797D0 (en) Vaccine